Study of CAR-T Cells Targeting BCMA for Previously CAR-T Treated Refractory/Relapsed Multiple Myeloma
Study of CAR-T Cells Targeting BCMA for Previously CAR-T Treated Refractory/Relapsed Multiple Myeloma is a PHASE1 clinical asset sponsored by Second Affiliated Hospital of Xi'an Jiaotong University in Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma Progression. SEO and diligence focus: CAR-T Re-treatment, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Multiple Myeloma
Modality: cell therapy
Target: CAR-T Re-treatment
Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CAR-T Re-treatment
View original source fields
Condition raw: Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma Progression
Condition normalized: Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma Progression
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: CAR-T Re-treatment
Target normalized: CAR-T Re-treatment